Le Boucher J, Eurengbiol, Farges MC, Minet R, Vasson MP, Cynober L
Scientific References Frequently Asked Questions Can GLP-1 medications specifically target belly fat
Egrifta SV launched commercially in 2020 March 25, 2025 Egrifta WR (tesamorelin F8) Approval Ready-to-use formulation approved no reconstitution required, improved patient convenience Approved Indication Tesamorelin (Egrifta) is specifically FDA-approved for: Indication: Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy HIV-associated lipodystrophy is a metabolic condition causing abnormal fat distribution, particularly visceral adipose tissue (VAT) accumulation around abdominal organs
while protection is demonstrated during active treatment, the long-term effects after stopping are not well established
Glutathione deficiency is a serious problem
Although implicated in neurodegenerative disorders but not currently in epilepsy, NLRC4 activation has also been found to be sensitive to mtROS production in astrocytes and contributes to gliosis (Samidurai et al., 2020)
